Back to top

Verastem’s RAMP 204 Trial Completion Signals New Momentum in KRAS G12C Lung Cancer

Verastem Inc ($VSTM) announced an update on their ongoing clinical study. Verastem, Inc. and Mirati Therapeutics Inc. have completed a phase 1/2 st...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Verastem, Inc. (VSTM)